Skip to content

Related Press Releases

April 27, 2022

High Court of Ireland Confirms Mallinckrodt Scheme of Arrangement

View Release
February 3, 2022

Mallinckrodt Plan of Reorganization Confirmed by U.S. Court

View Release
September 3, 2021

Mallinckrodt Reaches Settlements with the Official Committee of Opioid Related Creditors, the Official Committee of Unsecured Creditors and Second Lien Noteholders

View Release
March 10, 2021

Mallinckrodt Gains Support for Its Restructuring Support Agreement from Lenders Holding Approximately $1.3 Billion of Its First Lien Term Loans

View Release
October 14, 2020

Mallinckrodt Receives Court Approval of "First Day" Motions to Support Business Operations

View Release
October 12, 2020

Mallinckrodt Secures Broad Consensus with Key Stakeholders on Comprehensive Chapter 11 Restructuring

View Release

Commitment in Ireland

Stakeholder Factsheet

Customer Information

Supplier Information

Partner Information

Retiree Information

Trade Association and Advocacy Group Information

Specialty Generics/API Information and Resources

Stakeholder Factsheet

Customer Information

Supplier Information

Retiree Information

Trade Association and Advocacy Group Information

Additional Supplier Information – January 2021

Supplier Update Letter

Download PDF

Supplier Update FAQ

Download PDF

Investor Information

Term Sheet and Additional Materials

Term Sheet

Download PDF

Additional Materials

Download PDF

High Court of Ireland Confirms Mallinckrodt’s Scheme of Arrangement

Expects to Complete the Irish Examinership and Emerge from Chapter 11 in the Next Few Weeks

On October 12, 2020, Mallinckrodt announced important actions the Company is taking to strengthen its financial position and resolve a range of legal liabilities, enabling it to focus on achieving its long-term strategic plans. Mallinckrodt has worked throughout this process to build broad consensus for its plan of reorganization (the “Plan”) among key stakeholders, including:

  • Holders of a substantial majority of the Company’s guaranteed unsecured notes, first lien term loans and second lien notes;
  • 50 states and territories and the Plaintiffs’ Executive Committee in the opioid multidistrict litigation;
  • The Multi-State Governmental Entities Group, which represents more than 1,300 counties, municipalities, tribes and other governmental entities, across 38 states and territories, with opioid-related litigation against the Company;
  • Certain trade creditors;
  • Committees representing creditors’ interests in the case, including the Unsecured Creditors Committee (UCC) and Official Committee of Opioid Related Claimants (OCC); and
  • The Future Claims Representative.

On February 3, 2022, the U.S. Bankruptcy Court confirmed Mallinckrodt’s Plan.

Irish Examinership Proceedings

On February 14, 2022, the Directors of Mallinckrodt plc initiated a legal process in Ireland called an “Examinership” that is necessary to ensure that certain important aspects of the Plan are implemented under Irish law.

On April 27, 2022, the High Court of Ireland confirmed the scheme of arrangement (the “Scheme”) between the Company, its creditors and members as proposed by the Examiner of the Company, paving the way for Mallinckrodt to complete the Examinership and emerge from Chapter 11 in the next few weeks.

The Irish High Court also made an Order that the Scheme will become effective on the same date that the Plan becomes effective. This is when the Scheme will become binding on the Company, its creditors and members as a matter of Irish law, the Examinership proceedings will conclude, and the Company will cease to be under the protection of the Irish High Court.

Additional Information

Court filings and other information related to the court-supervised process are available:

On a separate website administered by the Company’s claims agent, Prime Clerk, at;

By calling Prime Clerk representatives toll-free in the U.S. and Canada at +1-877-467-1570 or +1-347-817-4093 for international calls; or

By emailing

For all supplier-related inquiries:

Call the Company toll-free in the U.S. at +1-833-954-2209 or +1-314-654-3008 for international calls; or

Email the Company at

Investor Relations
Daniel J. Speciale
Global Corporate Controller & Chief Investor Relations Officer

Michael Freitag / Aaron Palash / Aura Reinhard
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449

Government Affairs
Mark Tyndall
Senior Vice President, Government Affairs
& Chief Counsel, Litigation


Click here for information regarding Mallinckrodt’s Non-Opioid Claims Bar Date